Table 3:

Univariate analysis of factors associated with overall survival and time-to-relapse after HCT

			Overall Survival			Time-to-Relapse
		N	Events	HR (95% CI)	p-value	Events	HR (95% CI)	p-value
Residual disease
Flow MRD	Negative	35	7	reference	0.05	3	reference	0.016
	Positive	42	16	2.44 (1–5.97)		14	4.62(1.32–16.09)
Multi-gene NGS	Negative	52	13	reference	0.059	6	reference	0.003
	Positive	31	13	2.1 (0.97–4.55)		12	4.35 (1.63–11.6)
Tandem assessment	F−/M−	24	3	reference	0.072	2	reference	0.008
	F−/M+ or F−/M	18	7	3.96 (1.02–15.37)		3	2.31 (0.38–13.84)
	F+/M+	20	8	4.53 (1.19–17.18)		10	8.39 (1.83–38.38)
Blasts >5%	No	90	28	reference	0.011	16	reference	0.007
	Yes	14	8	2.78 (1.26–6.14)		6	3.64 (1.42–9.33)
Disease variables
T-AML	No	91	28	reference	0.009	18	reference	0.165
	Yes	13	8	2.87 (1.3–6.35)		4	2.16 (0.73–6.41)
Secondary AML	No	65	18	reference	0.076	12	reference	0.343
	Yes	39	18	1.81 (0.94–3.48)		10	1.5 (0.65–3.47)
HCT-CI	<3	51	12	reference	0.006	9	reference	0.184
	≥3	53	24	2.67 (1.33–5.37)		13	1.78 (0.76–4.17)
DRI	Low/Intermed	73	21	reference	0.013	10	reference	0.001
	High/very high	31	15	2.34 (1.2–4.57)		12	3.98 (1.71–9.25)
Transplant variables
Stem cell source	CB	19	7	reference	0.982	1	reference	0.315
	BM	12	4	0.92 (0.27–3.15)		3	4.92(0.51–47.34)
	PB	73	25	0.92 (0.4–2.13)		18	4.7 (0.63–35.2)
HLA matched	Yes	72	23	reference	0.337	18	reference	0.253
	No	32	13	1.4 (0.71–2.76)		4	0.53 (0.18–1.57)
CD34+ selection	No	75	25	reference	0.86	18	reference	0.228
	Yes	29	11	0.94 (0.46–1.91)		4	0.51 (0.17–1.52)
Conditioning	Ablative	59	18	reference	0.237	9	reference	0.1
	RIC	45	18	1.48 (0.77–2.86)		13	2.04 (0.87–4.78)

T-AML: therapy related AML, CB: Cord blood, BM: Bone marrow, PB: peripheral blood; RIC: reduced intensity conditioning, DRI: disease risk index, F: flow MRD, M: Residual mutations using NGS, HLA matched: matched sibling or matched unrelated donors assessed at 10 alleles (A, B, C, DR, DQ) and non-matched includes all mismatched related, unrelated and cord blood transplant.